Sobi Acquires Arthrosi Therapeutics
Sobi® (STO: SOBI), a prominent global biopharmaceutical company, has made a strategic move by entering into a definitive agreement to acquire Arthrosi Therapeutics, Inc. This acquisition signifies a major step in Sobi's commitment to addressing unmet needs in the treatment of gout, a prevalent form of inflammatory arthritis.
Enhancing the Gout Franchise
The addition of pozdeutinurad (AR882), an investigational next-generation oral URAT1 inhibitor, strengthens Sobi's existing gout franchise. Currently, pozdeutinurad is being evaluated in two fully enrolled global Phase 3 clinical studies aimed at managing progressive and tophaceous gout, with results anticipated soon. This new therapy offers updated treatment options for patients who have not been adequately served by current first-line therapies, aiming for both symptom relief and better quality of life.
Commitment to Gout Treatment
Guido Oelkers, President and CEO of Sobi, expressed optimism about the acquisition, highlighting its potential impact: "The acquisition of Arthrosi allows us to expand our gout pipeline with a highly differentiated new asset. Pozdeutinurad has the potential to become the therapy of choice for patients who experience persistent symptoms despite existing treatments. This aligns well with our strategic growth initiatives into the next decade."
Transaction Highlights
Under the terms of the agreement, Sobi will pay USD 950 million upfront, equivalent to approximately SEK 9.1 billion, for Arthrosi Therapeutics. In addition, there is potential for further payments totaling up to USD 550 million based on clinical, regulatory, and sales milestones achieved by the acquired asset.
The transaction is subject to typical closing conditions and is expected to finalize in the first half of 2026. To finance this acquisition, Sobi intends to utilize its existing credit facilities, supplemented by a new credit facility through Handelsbanken and Danske Bank.
Financial Implications
This acquisition is anticipated to significantly contribute to Sobi's long-term growth trajectory and financial performance. The company expects that integrating Arthrosi into its portfolio will enhance its revenue potential well into the future.
About Pozdeutinurad
Pozdeutinurad (AR882) is designed to address the needs of patients with progressive gout by effectively lowering serum uric acid levels and reducing flares and tophi. Previous Phase 2 studies showed promising outcomes, indicating a strong safety profile alongside sustained efficacy in reducing uric acid levels. The ongoing Phase 3 studies aim to confirm these findings and demonstrate the drug's potential as a transformative option for patients with gout.
About Arthrosi Therapeutics
Arthrosi Therapeutics, based in the United States, specializes in developing innovative treatments for gout. Their flagship product pozdeutinurad positions them at the forefront of solutions designed to manage this complex disease effectively. The company's strategic vision is to enhance patient outcomes through advanced clinical developments.
Future Steps and Conference Call
Following this significant acquisition, Sobi invites investors and media personnel to a conference call, where executives will discuss the implications of this move and provide insights into the drug's clinical development. This will be an opportunity for stakeholders to engage with the company's strategic direction and future product offerings.
Frequently Asked Questions
What is the focus of Sobi's acquisition?
Sobi's acquisition of Arthrosi Therapeutics focuses on enhancing its gout treatment pipeline with pozdeutinurad, a next-generation URAT1 inhibitor.
What is pozdeutinurad?
Pozdeutinurad (AR882) is an investigational therapy designed to treat gout by lowering uric acid levels and improving symptoms associated with the disease.
How much is Sobi paying for the acquisition?
Sobi is paying USD 950 million upfront, with further potential payments based on milestones related to pozdeutinurad's clinical and regulatory success.
When is the acquisition expected to close?
The acquisition is expected to close in the first half of 2026, pending customary closing conditions.
What are Sobi's expectations for pozdeutinurad?
Sobi expects pozdeutinurad to significantly enhance its growth strategy and provide an effective treatment option for patients inadequately treated by existing therapies.
